Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Overview
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Companies Involved in Therapeutics Development
ChemoCentryx Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Lassogen Inc
RAPT Therapeutics Inc
Tizo Therapeutics Inc
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Drug Profiles
BJY-809 – Drug Profile
Product Description
Mechanism Of Action
CB-5046 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CCX-6239 – Drug Profile
Product Description
Mechanism Of Action
History of Events
FLX-475 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas – Drug Profile
Product Description
Mechanism Of Action
History of Events
LAS-20X – Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibody to Target CCR4 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
RPT-193 – Drug Profile
Product Description
Mechanism Of Action
History of Events
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Dormant Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Discontinued Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – Product Development Milestones
Featured News & Press Releases
May 23, 2022: RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
Mar 28, 2022: RAPT Therapeutics announces biomarker data from phase 1b trial of RPT193 consistent with disease modification in atopic dermatitis
Oct 18, 2021: RAPT Therapeutics announces upcoming oral presentation of RPT193 phase 1b data at the 4th Inflammatory Skin Disease Summit
Sep 30, 2021: RAPT Therapeutics announces late-breaking oral presentation of positive results from phase 1b trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
Sep 20, 2021: RAPT Therapeutics to present RPT193 phase 1b data at 30th European Academy of Dermatology and Venereology Congress
Jun 14, 2021: RAPT Therapeutics reports positive topline results from phase 1b trial of RPT193 monotherapy in atopic dermatitis
Jun 13, 2021: RAPT Therapeutics to report top line data from phase 1b trial of RPT193 in atopic dermatitis
Mar 22, 2021: Rapt Therapeutics completes enrollment in phase 1b trial of RPT193 in atopic dermatitis
Nov 16, 2020: RAPT Therapeutics reports positive initial data from ongoing phase 1/2 clinical trial of FLX475 in multiple cancer indications
Nov 15, 2020: RAPT Therapeutics to announce initial data from phase 1/2 clinical trial of FLX475 in multiple cancer indications
May 15, 2020: RAPT Therapeutics highlights early results for RPT193 at Society for Investigative Dermatology Meeting
Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board
May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ChemoCentryx Inc, 2022
Pipeline by CohBar Inc, 2022
Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022
Pipeline by Lassogen Inc, 2022
Pipeline by RAPT Therapeutics Inc, 2022
Pipeline by Tizona Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022